TTY Biopharm Company Limited

eng.tty.com.tw

TTY Biopharm Co., Ltd. was established on July 22nd 1960. TTY is a Taiwan's leading pharmaceutical manufacturing company which specializes in the development of special formulations and new drugs. TTY focuses on research & development and innovation of antitumor and against severe infection's areas. We will continue to develop in healthcare product portfolio to support the physicians and patients with completed approach to disease treatment.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

CSL LIMITED ANNOUNCES TENDER OFFER TO ACQUIRE VIFOR PHARMA LTD

Vifor Pharma Group | December 15, 2021

news image

Global biotechnology leader CSL Limited and Vifor Pharma Ltd, a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion. CSL has offered to acquire Vifor Pharma in an all-cash tender offer of US$179.25 per share, payable in U.S. dollars.1 The offer assu...

Read More

WEBINAR HOSTED BY XTALKS TO COVER ACTIONS PHARMACEUTICAL COMMERCIAL TEAMS CAN TAKE TO STAY ON TRACK WITH 2020 GOALS

Xtalks | July 08, 2020

news image

COVID-19 swiftly changed the healthcare landscape around the world. There has been no rulebook for pharmaceutical commercialization during COVID-19. Pharmaceutical commercialization teams have had to quickly adapt to meet customer, community and business needs. Remote customer engagement and increased patient support services were the answer in the short term for pharmaceutical commercialization amid COVID-19. Longer term, teams will need to adapt brand strategy and executional approaches for in...

Read More

BUSINESS INSIGHTS

KEDRION BIOPHARMA GROWS IN NORTH AMERICA AS IT COMPLETES ACQUISITION OF PROMETIC

Kedrion Biopharma | October 19, 2021

news image

Kedrion Biopharma, the rapidly growing international biopharmaceuticals company that produces and distributes plasma-derived treatments for rare diseases, has announced that it has completed the acquisition in North America of the Prometic life sciences business. Prometic, which has a team of 130 employees in Laval, Québec, has developed the first ever FDA-approved treatment for Congenital Plasminogen Deficiency. The new drug, called Ryplazim®, , has been approved for t...

Read More

PHARMACY MARKET

HKSTP AND BOEHRINGER INGELHEIM VENTURE FUND LAUNCH CO-INCUBATION PROGRAMME TO FAST-TRACK R&D IN INFECTIOUS DISEASES AND IMMUNOLOGY

BIVF | June 18, 2022

news image

Hong Kong Science and Technology Parks Corporation is partnering global research-driven biopharmaceutical leader, Boehringer Ingelheim Venture Fund Limited in a strategic co-incubation collaboration to promote and nurture startups on research and development for infectious diseases and immunology. HKSTP is dedicated to collaborating with sector leaders in building the strongest I&T eco-system to help startups via business development, mentorship and investment initiatives. In ...

Read More
news image

PHARMA TECH

CSL LIMITED ANNOUNCES TENDER OFFER TO ACQUIRE VIFOR PHARMA LTD

Vifor Pharma Group | December 15, 2021

Global biotechnology leader CSL Limited and Vifor Pharma Ltd, a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion. CSL has offered to acquire Vifor Pharma in an all-cash tender offer of US$179.25 per share, payable in U.S. dollars.1 The offer assu...

Read More
news image

WEBINAR HOSTED BY XTALKS TO COVER ACTIONS PHARMACEUTICAL COMMERCIAL TEAMS CAN TAKE TO STAY ON TRACK WITH 2020 GOALS

Xtalks | July 08, 2020

COVID-19 swiftly changed the healthcare landscape around the world. There has been no rulebook for pharmaceutical commercialization during COVID-19. Pharmaceutical commercialization teams have had to quickly adapt to meet customer, community and business needs. Remote customer engagement and increased patient support services were the answer in the short term for pharmaceutical commercialization amid COVID-19. Longer term, teams will need to adapt brand strategy and executional approaches for in...

Read More
news image

BUSINESS INSIGHTS

KEDRION BIOPHARMA GROWS IN NORTH AMERICA AS IT COMPLETES ACQUISITION OF PROMETIC

Kedrion Biopharma | October 19, 2021

Kedrion Biopharma, the rapidly growing international biopharmaceuticals company that produces and distributes plasma-derived treatments for rare diseases, has announced that it has completed the acquisition in North America of the Prometic life sciences business. Prometic, which has a team of 130 employees in Laval, Québec, has developed the first ever FDA-approved treatment for Congenital Plasminogen Deficiency. The new drug, called Ryplazim®, , has been approved for t...

Read More
news image

PHARMACY MARKET

HKSTP AND BOEHRINGER INGELHEIM VENTURE FUND LAUNCH CO-INCUBATION PROGRAMME TO FAST-TRACK R&D IN INFECTIOUS DISEASES AND IMMUNOLOGY

BIVF | June 18, 2022

Hong Kong Science and Technology Parks Corporation is partnering global research-driven biopharmaceutical leader, Boehringer Ingelheim Venture Fund Limited in a strategic co-incubation collaboration to promote and nurture startups on research and development for infectious diseases and immunology. HKSTP is dedicated to collaborating with sector leaders in building the strongest I&T eco-system to help startups via business development, mentorship and investment initiatives. In ...

Read More